The relationship between skeletal-related events and bone scan index for the treatment of bone metastasis with breast cancer patients

Medicine (United States)

Volumn 93, Issue 28, 2014, Pages e269-

  Iwase, Toshiaki ^a,b   Yamamoto, Naohito ^a   Ichihara, Hironori ^a   Togawa, Takashi ^a   Nagashima, Takeshi ^b   Miyazaki, Masaru ^b  

^a CHIBA CANCER CENTER   (Japan)

^b Department of General Surgery   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE;

ADULT; AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; AUTOMATED BONE SCAN INDEX; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATION ANALYSIS; EVENT FREE SURVIVAL; FEMALE; GAMMA CAMERA; HUMAN; RETROSPECTIVE STUDY; BONE; BONE NEOPLASMS; BREAST NEOPLASMS; FOLLOW UP; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SCINTISCANNING; SECONDARY;

ADULT; AGED; BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84920120988     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000269     Document Type: Article

References (13)

1. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28: 5132-5139.
2. Erdi YE, Humm JL, Imbriaco M, et al. Quantitative bone metastases analysis based on image segmentation. J Nucl Med. 1997; 38: 1401-1406.
3. Ulmert D, Kaboteh R, Fox JJ, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012; 62: 78-84.
4. Horikoshi H, Kikuchi A, Onoguchi M, et al. Computer-aided diagnosis system for bone scintigrams from Japanese patients: importance of training database. Ann Nucl Med. 2012; 26: 622-626.
5. Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer followup and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31: 961-965.
6. Maffioli L, Florimonte L, Pagani L, et al. Current role of bone scan with phosphonates in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 2004; 31 (suppl 1): S143-S148.
7. Dennis ER, Jia X, Mezheritskiy IS, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012; 30: 519-524.
8. Kaboteh R, Gjertsson P, Leek H, et al. Progression of bone metastases in patients with prostate cancer -automated detection of new lesions and calculation of bone scan index. EJNMMI Res. 2013; 3: 64.
9. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007; 18: 1133-1144.
10. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999; 17: 948-957.
11. Brown JE, Cook RJ, Lipton A, et al. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat. 2010; 123: 767-779.
12. Koizumi M, Ogata E. Bone metabolic markers as gauges of metastasis to bone: a review. Ann Nucl Med. 2002; 16: 161-168.
13. Koizumi M, Yamada Y, Takiguchi T, et al. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol. 1995; 121: 542-548.